NR565 Advanced Pharmacology Fundamentals Midterm Examination | Chamberlain University 2026-2027
NR565 Advanced Pharmacology Fundamentals
Midterm Examination
Chamberlain University | 2026-2027 Curriculum | 75 Questions | Graded A+
Verified by Experts | Latest 2026/2027 Update
Section 1: Foundational Pharmacology Principles and Pharmacokinetics (Q1-Q15)
Q1: A 55-year-old patient is prescribed a medication with high first-pass metabolism. Which route of administration
would result in the HIGHEST bioavailability for this drug?
A. Oral tablet
B. Sublingual nitroglycerin [CORRECT]
C. Oral extended-release capsule
D. Rectal suppository
Correct Answer: B
Rationale: The sublingual route bypasses the hepatic portal circulation and first-pass metabolism, delivering drug directly into the
systemic venous circulation via the lingual veins. Oral tablets and extended-release capsules both undergo first-pass metabolism
through the portal vein to the liver, significantly reducing bioavailability. Rectal suppositories partially bypass first-pass metabolism
(approximately 50-70% enters the portal circulation), making sublingual the superior choice for maximum bioavailability with a high
first-pass drug. This principle is foundational in pharmacokinetics per Chamberlain NR 565 curriculum.
Q2: A nurse practitioner is reviewing a patient's medication profile and notes that warfarin is highly protein-bound (99%).
The patient is recently started on phenytoin for new-onset seizures. What is the MOST likely clinical consequence of this
drug interaction?
A. Decreased warfarin efficacy due to enhanced renal clearance
B. Increased free (unbound) warfarin concentration leading to elevated INR and bleeding risk [CORRECT]
C. No significant interaction because warfarin is metabolized by CYP2C9, not CYP2D6
D. Increased warfarin protein binding resulting in subtherapeutic INR
Correct Answer: B
Rationale: Both warfarin and phenytoin are highly protein-bound (greater than 95%) to albumin. When co-administered, phenytoin
displaces warfarin from albumin binding sites, increasing the free (pharmacologically active) fraction of warfarin. This leads to an
elevated INR and increased bleeding risk. Option A is incorrect because this is a displacement interaction, not a renal clearance issue.
Option C, while factually correct about CYP2C9 metabolism, does not address the primary protein-binding displacement mechanism.
Option D is the opposite of what occurs; displacement decreases binding, increasing free drug. This is a critical pharmacokinetic
interaction emphasized in NR 565.
Page 1
,NR565 Advanced Pharmacology Fundamentals Midterm Examination | Chamberlain University 2026-2027
Q3: A patient with end-stage renal disease (ESRD) on hemodialysis is prescribed a medication with a narrow therapeutic
index and a half-life of 36 hours. The drug is 80% protein-bound and primarily eliminated via renal tubular secretion.
Which adjustment is MOST appropriate?
A. Increase the dose to compensate for dialysis clearance
B. Extend the dosing interval based on the patient's estimated creatinine clearance [CORRECT]
C. No adjustment needed because the drug is highly protein-bound
D. Administer the drug immediately after dialysis sessions only
Correct Answer: B
Rationale: For a drug primarily eliminated via renal tubular secretion in ESRD, the most appropriate strategy is to extend the dosing
interval rather than increase the dose. Since the drug has a narrow therapeutic index, increasing the dose (Option A) risks toxicity.
Option C is incorrect because despite high protein binding, renal failure still impairs tubular secretion of the free fraction, and
accumulation occurs over time. Option D is overly rigid; post-dialysis supplementation may be needed but requires individualized
therapeutic drug monitoring. The Chamberlain NR 565 curriculum emphasizes that for renally cleared drugs with narrow therapeutic
indices, extending the dosing interval is the preferred approach to prevent accumulation and toxicity.
Q4: A patient takes rifampin for tuberculosis treatment. Which of the following mechanisms BEST explains why rifampin
reduces the effectiveness of oral contraceptives and warfarin simultaneously?
A. Rifampin induces hepatic CYP3A4 and CYP2C9 enzymes, increasing the metabolism of both drugs
[CORRECT]
B. Rifampin competes for albumin binding sites, displacing both drugs
C. Rifampin inhibits intestinal P-glycoprotein, reducing oral absorption of both drugs
D. Rifampin accelerates renal tubular secretion of both drugs
Correct Answer: A
Rationale: Rifampin is a potent inducer of multiple hepatic CYP450 enzymes, including CYP3A4 (which metabolizes estrogen and
progestin components of oral contraceptives) and CYP2C9 (which metabolizes S-warfarin, the more active enantiomer). This
induction increases the metabolic clearance of both drugs, reducing their serum concentrations and therapeutic effects. This leads to
unintended pregnancy risk and subtherapeutic anticoagulation. Option B describes a protein-binding displacement mechanism, which
is not rifampin's primary interaction pathway. Option C is incorrect because rifampin induces, not inhibits, P-glycoprotein. Option D
is incorrect because rifampin's interaction is primarily hepatic, not renal.
Q5: A 70-year-old patient with atrial fibrillation is started on amiodarone. Her maintenance dose of warfarin was
previously stable at 5 mg daily with an INR of 2.5. Two weeks later, her INR is 4.8. Which pharmacokinetic mechanism
BEST explains this interaction?
A. Amiodarone inhibits CYP2C9, reducing warfarin metabolism and increasing its serum concentration
[CORRECT]
B. Amiodarone induces CYP3A4, increasing warfarin clearance
C. Amiodarone displaces warfarin from protein-binding sites
D. Amiodarone decreases renal clearance of warfarin
Correct Answer: A
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing S-warfarin (the more potent
enantiomer). By inhibiting CYP2C9, amiodarone decreases warfarin's metabolic clearance, leading to increased serum warfarin
concentrations and a supra-therapeutic INR. This interaction is clinically significant and may require a 30-50% warfarin dose
reduction. Option B is incorrect because amiodarone inhibits, not induces, CYP enzymes. Option C is not the primary mechanism.
Option D is incorrect because warfarin is hepatically, not renally, eliminated. NR 565 emphasizes CYP450 inhibition as a major
source of warfarin interactions.
Page 2
, NR565 Advanced Pharmacology Fundamentals Midterm Examination | Chamberlain University 2026-2027
Q6: A patient is prescribed a drug with a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration if no loading dose is administered?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours [CORRECT]
Correct Answer: D
Rationale: Steady-state concentration is achieved after approximately 4-5 half-lives of a drug. For a drug with a 12-hour half-life: 4
half-lives equals 48 hours and 5 half-lives equals 60 hours. At 4 half-lives, approximately 94% of steady-state is reached, and at 5
half-lives, approximately 97% is reached. Therefore, 60 hours (5 half-lives) is the most accurate answer for practical clinical
purposes. Option A (12 hours, or 1 half-life) reaches only 50% of steady-state. Option B (24 hours, or 2 half-lives) reaches 75%.
Option C (48 hours, or 4 half-lives) reaches 94%, which is close but 60 hours is the more complete answer. This pharmacokinetic
principle is fundamental in NR 565.
Q7: A nurse practitioner is counseling a patient who takes verapamil for hypertension. The patient enjoys drinking
grapefruit juice daily. What is the MOST likely effect of this combination?
A. Decreased verapamil absorption due to intestinal CYP3A4 induction
B. Increased verapamil bioavailability due to inhibition of intestinal CYP3A4 by grapefruit juice
[CORRECT]
C. No significant interaction because verapamil is not a CYP3A4 substrate
D. Enhanced renal elimination of verapamil
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins (bergamottin and dihydroxybergamottin) that selectively inhibit intestinal
CYP3A4 enzymes, not hepatic CYP3A4. Verapamil is a CYP3A4 substrate that undergoes significant first-pass metabolism in the
intestinal wall. Inhibition of intestinal CYP3A4 increases verapamil's oral bioavailability, leading to higher serum concentrations,
increased pharmacological effects (hypotension, bradycardia, constipation), and potential toxicity. Option A is incorrect because
grapefruit juice inhibits, not induces, CYP3A4. Option C is factually incorrect; verapamil is metabolized by CYP3A4. Option D has no
pharmacological basis.
Q8: Which of the following statements about enterohepatic recirculation is CORRECT?
A. It increases the rate of drug elimination from the body
B. It occurs when a drug is excreted in bile, reabsorbed in the intestine, and returns to the liver via the portal
vein [CORRECT]
C. It is only relevant for drugs that are exclusively renally eliminated
D. It prevents drug conjugation in the liver
Correct Answer: B
Rationale: Enterohepatic recirculation is a pharmacokinetic process in which a drug (or its metabolite) is conjugated in the liver
(typically via glucuronidation), excreted into bile, stored in the gallbladder, released into the small intestine, and then reabsorbed
back into the portal circulation. Intestinal bacteria deconjugate the metabolite back to the parent drug, allowing reabsorption. This
process prolongs the drug's half-life and duration of action. Option A is incorrect because it actually decreases the rate of elimination.
Option C is incorrect because enterohepatic recirculation involves biliary, not renal, excretion. Option D is incorrect because
conjugation is a prerequisite for biliary excretion and subsequent recirculation.
Page 3
NR565 Advanced Pharmacology Fundamentals
Midterm Examination
Chamberlain University | 2026-2027 Curriculum | 75 Questions | Graded A+
Verified by Experts | Latest 2026/2027 Update
Section 1: Foundational Pharmacology Principles and Pharmacokinetics (Q1-Q15)
Q1: A 55-year-old patient is prescribed a medication with high first-pass metabolism. Which route of administration
would result in the HIGHEST bioavailability for this drug?
A. Oral tablet
B. Sublingual nitroglycerin [CORRECT]
C. Oral extended-release capsule
D. Rectal suppository
Correct Answer: B
Rationale: The sublingual route bypasses the hepatic portal circulation and first-pass metabolism, delivering drug directly into the
systemic venous circulation via the lingual veins. Oral tablets and extended-release capsules both undergo first-pass metabolism
through the portal vein to the liver, significantly reducing bioavailability. Rectal suppositories partially bypass first-pass metabolism
(approximately 50-70% enters the portal circulation), making sublingual the superior choice for maximum bioavailability with a high
first-pass drug. This principle is foundational in pharmacokinetics per Chamberlain NR 565 curriculum.
Q2: A nurse practitioner is reviewing a patient's medication profile and notes that warfarin is highly protein-bound (99%).
The patient is recently started on phenytoin for new-onset seizures. What is the MOST likely clinical consequence of this
drug interaction?
A. Decreased warfarin efficacy due to enhanced renal clearance
B. Increased free (unbound) warfarin concentration leading to elevated INR and bleeding risk [CORRECT]
C. No significant interaction because warfarin is metabolized by CYP2C9, not CYP2D6
D. Increased warfarin protein binding resulting in subtherapeutic INR
Correct Answer: B
Rationale: Both warfarin and phenytoin are highly protein-bound (greater than 95%) to albumin. When co-administered, phenytoin
displaces warfarin from albumin binding sites, increasing the free (pharmacologically active) fraction of warfarin. This leads to an
elevated INR and increased bleeding risk. Option A is incorrect because this is a displacement interaction, not a renal clearance issue.
Option C, while factually correct about CYP2C9 metabolism, does not address the primary protein-binding displacement mechanism.
Option D is the opposite of what occurs; displacement decreases binding, increasing free drug. This is a critical pharmacokinetic
interaction emphasized in NR 565.
Page 1
,NR565 Advanced Pharmacology Fundamentals Midterm Examination | Chamberlain University 2026-2027
Q3: A patient with end-stage renal disease (ESRD) on hemodialysis is prescribed a medication with a narrow therapeutic
index and a half-life of 36 hours. The drug is 80% protein-bound and primarily eliminated via renal tubular secretion.
Which adjustment is MOST appropriate?
A. Increase the dose to compensate for dialysis clearance
B. Extend the dosing interval based on the patient's estimated creatinine clearance [CORRECT]
C. No adjustment needed because the drug is highly protein-bound
D. Administer the drug immediately after dialysis sessions only
Correct Answer: B
Rationale: For a drug primarily eliminated via renal tubular secretion in ESRD, the most appropriate strategy is to extend the dosing
interval rather than increase the dose. Since the drug has a narrow therapeutic index, increasing the dose (Option A) risks toxicity.
Option C is incorrect because despite high protein binding, renal failure still impairs tubular secretion of the free fraction, and
accumulation occurs over time. Option D is overly rigid; post-dialysis supplementation may be needed but requires individualized
therapeutic drug monitoring. The Chamberlain NR 565 curriculum emphasizes that for renally cleared drugs with narrow therapeutic
indices, extending the dosing interval is the preferred approach to prevent accumulation and toxicity.
Q4: A patient takes rifampin for tuberculosis treatment. Which of the following mechanisms BEST explains why rifampin
reduces the effectiveness of oral contraceptives and warfarin simultaneously?
A. Rifampin induces hepatic CYP3A4 and CYP2C9 enzymes, increasing the metabolism of both drugs
[CORRECT]
B. Rifampin competes for albumin binding sites, displacing both drugs
C. Rifampin inhibits intestinal P-glycoprotein, reducing oral absorption of both drugs
D. Rifampin accelerates renal tubular secretion of both drugs
Correct Answer: A
Rationale: Rifampin is a potent inducer of multiple hepatic CYP450 enzymes, including CYP3A4 (which metabolizes estrogen and
progestin components of oral contraceptives) and CYP2C9 (which metabolizes S-warfarin, the more active enantiomer). This
induction increases the metabolic clearance of both drugs, reducing their serum concentrations and therapeutic effects. This leads to
unintended pregnancy risk and subtherapeutic anticoagulation. Option B describes a protein-binding displacement mechanism, which
is not rifampin's primary interaction pathway. Option C is incorrect because rifampin induces, not inhibits, P-glycoprotein. Option D
is incorrect because rifampin's interaction is primarily hepatic, not renal.
Q5: A 70-year-old patient with atrial fibrillation is started on amiodarone. Her maintenance dose of warfarin was
previously stable at 5 mg daily with an INR of 2.5. Two weeks later, her INR is 4.8. Which pharmacokinetic mechanism
BEST explains this interaction?
A. Amiodarone inhibits CYP2C9, reducing warfarin metabolism and increasing its serum concentration
[CORRECT]
B. Amiodarone induces CYP3A4, increasing warfarin clearance
C. Amiodarone displaces warfarin from protein-binding sites
D. Amiodarone decreases renal clearance of warfarin
Correct Answer: A
Rationale: Amiodarone is a potent inhibitor of CYP2C9, the primary enzyme responsible for metabolizing S-warfarin (the more potent
enantiomer). By inhibiting CYP2C9, amiodarone decreases warfarin's metabolic clearance, leading to increased serum warfarin
concentrations and a supra-therapeutic INR. This interaction is clinically significant and may require a 30-50% warfarin dose
reduction. Option B is incorrect because amiodarone inhibits, not induces, CYP enzymes. Option C is not the primary mechanism.
Option D is incorrect because warfarin is hepatically, not renally, eliminated. NR 565 emphasizes CYP450 inhibition as a major
source of warfarin interactions.
Page 2
, NR565 Advanced Pharmacology Fundamentals Midterm Examination | Chamberlain University 2026-2027
Q6: A patient is prescribed a drug with a half-life of 12 hours. Approximately how long will it take to reach steady-state
concentration if no loading dose is administered?
A. 12 hours
B. 24 hours
C. 48 hours
D. 60 hours [CORRECT]
Correct Answer: D
Rationale: Steady-state concentration is achieved after approximately 4-5 half-lives of a drug. For a drug with a 12-hour half-life: 4
half-lives equals 48 hours and 5 half-lives equals 60 hours. At 4 half-lives, approximately 94% of steady-state is reached, and at 5
half-lives, approximately 97% is reached. Therefore, 60 hours (5 half-lives) is the most accurate answer for practical clinical
purposes. Option A (12 hours, or 1 half-life) reaches only 50% of steady-state. Option B (24 hours, or 2 half-lives) reaches 75%.
Option C (48 hours, or 4 half-lives) reaches 94%, which is close but 60 hours is the more complete answer. This pharmacokinetic
principle is fundamental in NR 565.
Q7: A nurse practitioner is counseling a patient who takes verapamil for hypertension. The patient enjoys drinking
grapefruit juice daily. What is the MOST likely effect of this combination?
A. Decreased verapamil absorption due to intestinal CYP3A4 induction
B. Increased verapamil bioavailability due to inhibition of intestinal CYP3A4 by grapefruit juice
[CORRECT]
C. No significant interaction because verapamil is not a CYP3A4 substrate
D. Enhanced renal elimination of verapamil
Correct Answer: B
Rationale: Grapefruit juice contains furanocoumarins (bergamottin and dihydroxybergamottin) that selectively inhibit intestinal
CYP3A4 enzymes, not hepatic CYP3A4. Verapamil is a CYP3A4 substrate that undergoes significant first-pass metabolism in the
intestinal wall. Inhibition of intestinal CYP3A4 increases verapamil's oral bioavailability, leading to higher serum concentrations,
increased pharmacological effects (hypotension, bradycardia, constipation), and potential toxicity. Option A is incorrect because
grapefruit juice inhibits, not induces, CYP3A4. Option C is factually incorrect; verapamil is metabolized by CYP3A4. Option D has no
pharmacological basis.
Q8: Which of the following statements about enterohepatic recirculation is CORRECT?
A. It increases the rate of drug elimination from the body
B. It occurs when a drug is excreted in bile, reabsorbed in the intestine, and returns to the liver via the portal
vein [CORRECT]
C. It is only relevant for drugs that are exclusively renally eliminated
D. It prevents drug conjugation in the liver
Correct Answer: B
Rationale: Enterohepatic recirculation is a pharmacokinetic process in which a drug (or its metabolite) is conjugated in the liver
(typically via glucuronidation), excreted into bile, stored in the gallbladder, released into the small intestine, and then reabsorbed
back into the portal circulation. Intestinal bacteria deconjugate the metabolite back to the parent drug, allowing reabsorption. This
process prolongs the drug's half-life and duration of action. Option A is incorrect because it actually decreases the rate of elimination.
Option C is incorrect because enterohepatic recirculation involves biliary, not renal, excretion. Option D is incorrect because
conjugation is a prerequisite for biliary excretion and subsequent recirculation.
Page 3
